Emergent Biosolutions Inc. (NYSE:EBS) has received a consensus rating of “Buy” from the six research firms that are covering the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $39.40.

Several equities analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Wells Fargo & Co. set a $41.00 price objective on shares of Emergent Biosolutions and gave the stock a “buy” rating in a research report on Saturday, October 1st. JPMorgan Chase & Co. lowered their price objective on shares of Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating on the stock in a research report on Friday, August 5th. Chardan Capital reiterated a “buy” rating and set a $47.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, November 9th. Finally, Cowen and Company reiterated a “hold” rating and set a $33.00 price objective on shares of Emergent Biosolutions in a research report on Sunday, August 7th.

Shares of Emergent Biosolutions (NYSE:EBS) opened at 29.42 on Thursday. The firm has a market capitalization of $1.19 billion, a P/E ratio of 27.86 and a beta of 1.03. Emergent Biosolutions has a one year low of $24.47 and a one year high of $44.38. The company has a 50-day moving average price of $28.91 and a 200 day moving average price of $32.43.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.32. Emergent Biosolutions had a net margin of 9.12% and a return on equity of 10.42%. The firm had revenue of $142.91 million for the quarter, compared to analysts’ expectations of $112.30 million. During the same period in the previous year, the company posted $0.93 EPS. The company’s quarterly revenue was down 9.8% compared to the same quarter last year. Analysts expect that Emergent Biosolutions will post $1.02 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the stock. Raymond James & Associates raised its stake in shares of Emergent Biosolutions by 0.4% in the second quarter. Raymond James & Associates now owns 8,456 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 36 shares during the period. New York State Teachers Retirement System raised its stake in shares of Emergent Biosolutions by 0.3% in the second quarter. New York State Teachers Retirement System now owns 36,755 shares of the biopharmaceutical company’s stock worth $1,034,000 after buying an additional 100 shares during the period. Municipal Employees Retirement System of Michigan raised its stake in shares of Emergent Biosolutions by 1.2% in the third quarter. Municipal Employees Retirement System of Michigan now owns 9,450 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 110 shares during the period. Hancock Holding Co. raised its stake in shares of Emergent Biosolutions by 0.5% in the second quarter. Hancock Holding Co. now owns 24,130 shares of the biopharmaceutical company’s stock worth $679,000 after buying an additional 130 shares during the period. Finally, Howe & Rusling Inc. raised its stake in shares of Emergent Biosolutions by 3.0% in the second quarter. Howe & Rusling Inc. now owns 4,875 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 140 shares during the period. 89.99% of the stock is owned by institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

5 Day Chart for NYSE:EBS

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.